vs
Side-by-side financial comparison of ALPHA PRO TECH LTD (APT) and AVANOS MEDICAL, INC. (AVNS). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $13.9M, roughly 13.0× ALPHA PRO TECH LTD). ALPHA PRO TECH LTD runs the higher net margin — 5.0% vs -0.7%, a 5.8% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs 0.3%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $51.0K). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 1.4%).
Alpha Pro Tech Ltd is a leading developer, manufacturer and marketer of disposable protective apparel, face masks, and building supply products including weather-resistant barriers. It primarily serves the healthcare, industrial, and construction sectors, with core operating markets concentrated in North America.
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
APT vs AVNS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $13.9M | $180.9M |
| Net Profit | $698.0K | $-1.3M |
| Gross Margin | 37.1% | 47.5% |
| Operating Margin | 6.9% | 1.4% |
| Net Margin | 5.0% | -0.7% |
| Revenue YoY | 0.3% | 0.7% |
| Net Profit YoY | -17.6% | 99.7% |
| EPS (diluted) | $0.06 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.9M | $180.9M | ||
| Q3 25 | $14.8M | $177.8M | ||
| Q2 25 | $16.7M | $175.0M | ||
| Q1 25 | $13.8M | $167.5M | ||
| Q4 24 | $13.8M | $179.6M | ||
| Q3 24 | $14.3M | $170.4M | ||
| Q2 24 | $16.3M | $171.7M | ||
| Q1 24 | $13.5M | $166.1M |
| Q4 25 | $698.0K | $-1.3M | ||
| Q3 25 | $976.0K | $-1.4M | ||
| Q2 25 | $1.2M | $-76.8M | ||
| Q1 25 | $613.0K | $6.6M | ||
| Q4 24 | $847.0K | $-397.3M | ||
| Q3 24 | $862.0K | $4.3M | ||
| Q2 24 | $1.6M | $1.8M | ||
| Q1 24 | $576.0K | $-900.0K |
| Q4 25 | 37.1% | 47.5% | ||
| Q3 25 | 39.7% | 48.4% | ||
| Q2 25 | 36.8% | 52.6% | ||
| Q1 25 | 39.0% | 53.6% | ||
| Q4 24 | 37.6% | 54.6% | ||
| Q3 24 | 38.5% | 54.5% | ||
| Q2 24 | 42.0% | 55.7% | ||
| Q1 24 | 40.2% | 57.1% |
| Q4 25 | 6.9% | 1.4% | ||
| Q3 25 | 7.4% | 0.1% | ||
| Q2 25 | 8.0% | -42.6% | ||
| Q1 25 | 3.3% | 6.1% | ||
| Q4 24 | 4.9% | -233.0% | ||
| Q3 24 | 5.2% | 7.0% | ||
| Q2 24 | 10.5% | 3.7% | ||
| Q1 24 | 2.4% | 2.4% |
| Q4 25 | 5.0% | -0.7% | ||
| Q3 25 | 6.6% | -0.8% | ||
| Q2 25 | 7.5% | -43.9% | ||
| Q1 25 | 4.4% | 3.9% | ||
| Q4 24 | 6.1% | -221.2% | ||
| Q3 24 | 6.0% | 2.5% | ||
| Q2 24 | 10.1% | 1.0% | ||
| Q1 24 | 4.3% | -0.5% |
| Q4 25 | $0.06 | $-0.02 | ||
| Q3 25 | $0.09 | $-0.03 | ||
| Q2 25 | $0.12 | $-1.66 | ||
| Q1 25 | $0.06 | $0.14 | ||
| Q4 24 | $0.07 | $-8.64 | ||
| Q3 24 | $0.08 | $0.09 | ||
| Q2 24 | $0.15 | $0.04 | ||
| Q1 24 | $0.05 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.0M | $89.8M |
| Total DebtLower is stronger | — | $90.3M |
| Stockholders' EquityBook value | $62.5M | $778.2M |
| Total Assets | $74.1M | $1.1B |
| Debt / EquityLower = less leverage | — | 0.12× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.0M | $89.8M | ||
| Q3 25 | $17.7M | $70.5M | ||
| Q2 25 | $14.5M | $90.3M | ||
| Q1 25 | $13.4M | $97.0M | ||
| Q4 24 | $18.6M | $107.7M | ||
| Q3 24 | $18.4M | $89.0M | ||
| Q2 24 | $16.2M | $92.2M | ||
| Q1 24 | $18.5M | $75.8M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $93.4M | ||
| Q2 25 | — | $95.7M | ||
| Q1 25 | — | $98.0M | ||
| Q4 24 | — | $125.3M | ||
| Q3 24 | — | $152.6M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $167.2M |
| Q4 25 | $62.5M | $778.2M | ||
| Q3 25 | $62.5M | $778.0M | ||
| Q2 25 | $62.2M | $776.3M | ||
| Q1 25 | $61.7M | $839.4M | ||
| Q4 24 | $62.2M | $828.5M | ||
| Q3 24 | $62.1M | $1.2B | ||
| Q2 24 | $62.0M | $1.2B | ||
| Q1 24 | $61.6M | $1.2B |
| Q4 25 | $74.1M | $1.1B | ||
| Q3 25 | $73.9M | $1.1B | ||
| Q2 25 | $73.2M | $1.0B | ||
| Q1 25 | $72.2M | $1.1B | ||
| Q4 24 | $73.7M | $1.2B | ||
| Q3 24 | $73.3M | $1.7B | ||
| Q2 24 | $72.7M | $1.7B | ||
| Q1 24 | $72.7M | $1.7B |
| Q4 25 | — | 0.12× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | — | 0.12× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.13× | ||
| Q1 24 | — | 0.14× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $318.0K | $28.2M |
| Free Cash FlowOCF − Capex | $51.0K | $21.3M |
| FCF MarginFCF / Revenue | 0.4% | 11.8% |
| Capex IntensityCapex / Revenue | 1.9% | 3.8% |
| Cash ConversionOCF / Net Profit | 0.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.7M | $43.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $318.0K | $28.2M | ||
| Q3 25 | $3.9M | $14.0M | ||
| Q2 25 | $2.1M | $6.8M | ||
| Q1 25 | $-4.0M | $25.7M | ||
| Q4 24 | $2.4M | $57.9M | ||
| Q3 24 | $5.3M | $23.0M | ||
| Q2 24 | $-873.0K | $27.8M | ||
| Q1 24 | $-1.2M | $-8.0M |
| Q4 25 | $51.0K | $21.3M | ||
| Q3 25 | $3.8M | $7.0M | ||
| Q2 25 | $1.9M | $-4.2M | ||
| Q1 25 | $-4.1M | $19.0M | ||
| Q4 24 | $970.0K | $53.1M | ||
| Q3 24 | $3.2M | $20.0M | ||
| Q2 24 | $-1.0M | $21.9M | ||
| Q1 24 | $-1.3M | $-12.1M |
| Q4 25 | 0.4% | 11.8% | ||
| Q3 25 | 25.9% | 3.9% | ||
| Q2 25 | 11.7% | -2.4% | ||
| Q1 25 | -29.6% | 11.3% | ||
| Q4 24 | 7.0% | 29.6% | ||
| Q3 24 | 22.3% | 11.7% | ||
| Q2 24 | -6.2% | 12.8% | ||
| Q1 24 | -9.3% | -7.3% |
| Q4 25 | 1.9% | 3.8% | ||
| Q3 25 | 0.7% | 3.9% | ||
| Q2 25 | 0.8% | 6.3% | ||
| Q1 25 | 1.0% | 4.0% | ||
| Q4 24 | 10.4% | 2.7% | ||
| Q3 24 | 15.1% | 1.8% | ||
| Q2 24 | 0.8% | 3.4% | ||
| Q1 24 | 0.6% | 2.5% |
| Q4 25 | 0.46× | — | ||
| Q3 25 | 4.02× | — | ||
| Q2 25 | 1.68× | — | ||
| Q1 25 | -6.46× | 3.89× | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 6.18× | 5.35× | ||
| Q2 24 | -0.53× | 15.44× | ||
| Q1 24 | -2.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APT
Segment breakdown not available.
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
